Código QR

Tofogliflozin attenuates liver steatosis and fibrosis in non-diabetic non-alcoholic steatohepatitis mice

Abstract Background Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease with increasing global prevalence. Although diabetes is a major factor in NAFLD progression, up to 75% of the patients with NAFLD do not have diabetes. Tofogliflozin (Tofo), a sodium-glucose cotr...

Descrición completa

Gardado en:
Principais autores: Yoshinori Ozono, Hiroshi Kawakami, Hiroshi Hatada, Naomi Uchiyama, Souichiro Ogawa, Keisuke Uchida, Hotaka Tamura, Yuri Komaki, Kenichi Nakamura, Hisayoshi Iwakiri, Satoru Hasuike, Kenji Nagata
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2026-01-01
Series:BMC Gastroenterology
Assuntos:
NAFLD
NASH
Tofogliflozin
Diabetes
CDAHFD
Acceso en liña:https://doi.org/10.1186/s12876-026-04610-1
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares